A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers

NCT02923934 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Gastrointestinal Cancer
Neuroendocrine Tumours
Malignant Female Reproductive System Neoplasm

Interventions

DRUG: Ipilimumab
DRUG: Nivolumab

Sponsor

Olivia Newton-John Cancer Research Institute

Collaborators

[object Object]